Recently, Sichuan Xieli Pharmaceutical Co., Ltd. received an EU-GMP certificate from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, which is valid in 25 EU countries. This marks that Xieli Pharmaceutical's three products, irinotecan hydrochloride, troxerutin, and rutin, will enter the EU market as raw materials. At present, only a few enterprises in China have passed the GMP certification of the European Union. Sichuan Xieli Pharmaceutical Co., Ltd. is a key enterprise in the production of plant-based export raw materials in our city, specializing in plant planting, natural active ingredient extraction and derivative synthesis research, anti-tumor series and drug formulation production. The company has undertaken a major scientific and technological achievement transformation project in our city in 2011- "Industrialization of first-line anti-tumor drug irinotecan hydrochloride raw materials", which has obtained GMP certification from the European Union, This will help drive the development and upgrading of plant extract production enterprises in our city from exporting plant extracts and pharmaceutical intermediates to exporting raw materials.

　　Transfer to: Chengdu Science and Technology Bureau